Table 1 Small molecule MEK1/2 inhibitors in clinical trials
From: From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Inhibitor | Company | Phase | Status |
|---|---|---|---|
CI-1040 | Pfizer | Phase II | Development stopped |
PD0325901 | Pfizer | Phase I/II | Development stopped |
AZD6244 | Array BioPharma/ AstraZeneca | Phase II | In progress |
GDC-0973 | Exelixis/ Genentech | Phase I | In progress |
RDEA119 | Ardea Biosciences/ Bayer | Phase I/II | In progress |
GSK1120212 | GlaxoSmithKline | Phase I/II | In progress |
AZD8330 | Array BioPharma/ AstraZeneca | Phase I | In progress |
RO5126766 | Hoffmann La Roche | Phase I | In progress |
RO4987655 | Hoffmann La Roche | Phase I | In progress |
TAK-733 | Millenium Pharmaceuticals | Phase I | In progress |
AS703026 | EMD Serono | Phase I | In progress |